Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia
Dong Cao,Xie Shi-ping,Chen Qi-bao,Yuan Yong-gui,Qun Fang
2005-01-01
Abstract:Aim: To observe the sexual disturbance in male patients with schizophrenia caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids. Methods: Totally 100 male inpatients with schizophrenia in the Brain Hospital affiliated to Nanjing Medical University between October 2003 and October 2004 were randomly divided into chlorpromazine group (n=25), risperidone group (n= 25), quetiapine group(n=25) and olanzapine group (n=25).There were insignificant differences in age, educational background, disease course, economic status, couples'relationship and the baseline scores of positive and negative syndrome scale (PANSS). The patients in the four groups were treated with chlorpromazine (25 mg/tablet), risperidone (1 mg/tablet), quetiapine (200 mg/tablet) and olanzapine (5 mg/tablet) respectively. The levels of blood glucose, triaglyceride, high density lipoprotein cholesterol (HDL-C),low density lipoprotein cholestero (LDL-C),apolipoprotein A and apolipoprotein B were detected with enzyme chromatometry,direct method and immunoturbidimetry before treatment and 4 and 8 weeks after treatment. The baseline data of sexual function of the patients were provided by their spouses before treatment, and they were further evaluated after their psychiatric symptoms were relieved. The mental status of the patients with schizophrenia were generally relieved after 4 weeks, and rehabilitated after 8 weeks, and they could finished the questionnaire inventory independently. The sexual function of the patients were assessed with the self-designed male sexual function scale before treatment and 8,12 and 16 weeks after treatment, the scale included 4 factor scores of sexuality, sexual arousal, sexual orgasm and sexual satisfactory degree, and the general factor score of sexual function was the sum up of the 4 factor scores. Results: There were 17, 19, 19 and 18 cases in the chlorpromazine group, risperidone group, quetiapine group and olanzapine group involved in the analysis of results respectively. (1) The incidence rate of hyposexuality: It was significantly lower in the quetiapine group than in the chlorpromazine group and risperidone group at 8 weeks (21.1%, 58.8%, 63.2%, F=5.386, 6.909, P< 0.05). (2) Incidence rate of difficulty in sexual arousal: It was significantly lower in the quetiapine group than in the chlorpromazine group at 8, 12 and 16 weeks (21.1%, 21.1%, (1) 5.8%; 64.7%, 70.6%, 70.6%, F=7.034, 6.916,11.9, P< 0.05), and also remarkably lower than those in the risperidone group (63.2%, 47.4%, 57.9%, F=6.909, 2.923, 7.238, P < 0.05). (3) Level of blood glucose: After 8 weeks, it was significantly than the baseline level in the chlorpromazine group (F=7.224,P < 0.01) and olanzapine group (F=3.187,P= 0.05), but not significantly different from the baseline level in the risperidone group and quetiapine group (P>0.05). (4) Level of triglyceride: At 8 weeks, it was significantly higher than the baseline level in the olanzapine group (F=8.344, P < 0.05),but not significantly different from the baseline level in the chlorpromazine group, risperidone group and quetiapine group (P>0.05). Conclusion: Chlorpromazine and risperidone have different influence on the sexuality and sexual arousal.Chlorpromazine can lead to the obvious increase of the levels of blood glucose, LDL-C and apolipoprotein B. Quetiapine has little influence on levels of blood glucose, blood lipids and sexual arousal. Olanzapine has certain influence on blood glucose, triglyceride, apolipoprotein B, sexuality and sexual arousal.